ONGOING
No. Research Title Investigator Status
1 AEGIS II – A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subject with Acute Coronary Syndrome Dato’ Sri Dr. Haji Azhari Rosman Enrollment
2 APPIRED III – Preventing Oxidative Stress Induced Ischemic Injury and Systemic Inflammation Complications During and After Invasive Cardiac Surgery with Alkaline Phosphatase Dr. Pau Kiew Kong Enrollment
3 ABILITY DIABETES – Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diebetes Mellitus Global. Dato’ Dr. Amin Ariff Nuruddin Enrollment
4 COMBINE-INTERVENE – COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events. Dato’ Dr. Amin Ariff Nuruddin Enrollment
5 LEADR: Lead Evaluation for Defibrillation and Reliability Dr. Surinder Kaur Khelae Enrollment
6 CTO Registry using the HYBRID CTO ALGORITHM at IJN. (Device : Crossboss & Stingray) Datuk Dr. Shaiful Azmi Yahaya Enrollment
7 FINEARTS – A multicentre, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure(NYHA II-IV) and EF ≥40% Dr. Teoh Chee Kiang Enrollment
8 DEDICATE REGISTRY – A Post Market Registry of Abluminum® Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetic Mellitus Dato’ Sri Dr. Haji Azhari Rosman Enrollment
9 GSR DEFINE: Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE study Dato’ Dr. Amin Ariff Nuruddin Enrollment
10 FIM-IBS – A Prospective, Non-randomized, Open lable, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System Datuk Dr. Shaiful Azmi Yahaya Enrollment
11 ZEUS-Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation Dato’ Sri Dr. Haji Azhari Rosman Enrollment
12 MID-Q Response Datuk Dr. Azlan Hussin Enrollment
13 NEOS-APAC-Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO Mr. Paneer Selvam Enrollment
14 RESTORE: A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging Dr. Geetha A/P Kandavello @ Kandhavel Enrollment
15 TOMORROW – A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children with Pulmonary Arterial Hypertension Dr. Geetha A/P Kandavello @ Kandhavel Enrollment
16 VFAHF STUDY – Ventricle from Atrium Heart Failure Clinical Study (VFAHF) Datuk Dr. Azlan Hussin Enrollment
17 SALTO – A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension Dr. Geetha A/P Kandavello @ Kandhavel Enrollment
18 SCORE REGISTRY: Sequent® SCB ‘’All Comers’’ Post Market Clinical Follow up (PMCF) Dato’ Dr. Amin Ariff Nuruddin Enrollment
19 STRIDE: Effects of semaglutide on functional capacity in patients withtype 2 diabetes and peripheral arterial disease Datuk Dr. Shaiful Azmi Yahaya Enrollment
20 PRIME-FFR: Prognostic impact of lesion-specific hemodynamic index and disease characteristics in patients with coronary artery disease assessed by fractional flow reserve Dato’ Sri Dr. Haji Azhari Rosman Enrollment
       
No. Research Title Investigator Status
1 BIOLUX P-III REGISTRY: BIOTRONIK-A Prospective, International, Multi-Centre, Post-Market All-Comers Registry To Assess The Clinical Performance Of The Passeo-18 Lux Paclitaxel Releasing Balloon Catheter In Infraguinal Arteries -III Datuk Dr. Shaiful Azmi Yahaya Follow Up
2 Meres-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study Of Meres100 Sirolimus Eluting Bioresorbable Vascular Scaffold System In The Treatment Of De-Novo Native Coronary Artery Lesions Dato’ Dr. Amin Ariff Nuruddin Follow Up
3 ABSORB BVS: Comparative Study In Real World Use Of The ABSORB Bioresorbable Vascular Scaffold In De Novo Coronary Artery Disease Among Diabetes And Non-Diabetes Patient In Institut Jantung Negara, Malaysia: A Prospective Post-Marketing Single-Center Registry Datuk Dr. Shaiful Azmi Yahaya Follow Up
4 CONSEQUENT ALL COMERS: Clinical PMCF on Peripheral Arteries treated with SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population Datuk Dr. Shaiful Azmi Yahaya Follow Up
5 ISCHEMIA – International Study of Comparative Health Effectiveness With Medical and Invasive Approaches Datuk Dr. Ahmad Khairuddin Mohamed Yusof Follow Up
6 The EASTBOURNE Registry: The All-comers Sirolimus-coated balloon European registry. Dato’ Dr. Amin Ariff Nuruddin Follow Up
7 SCB DE-NOVO STUDY: Treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter Dato’ Dr. Amin Ariff Nuruddin Follow Up
8 BIOSOLVE-IV REGISTRY: Safety And Performance In De Novo Lesion Of Native Coronary Arteries With Magmaris – Registry Data Dato’ Dr. Amin Ariff Nuruddin Follow Up
9 MYHF: Malaysian National Heart Failure Registry Dato’ Dr. Azmee Bin Mohd Ghazi Follow Up
10 SELECT STUDY: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity Dato’ Sri Dr. Haji Azhari Rosman Follow Up
11 BGSAMIRP: Blood-based Genomic Signatures in Acute Myocardial Infarction Risk Prediction Dato’ Dr. Amin Ariff Nuruddin Follow Up
12 CAAN-AF: Cardiac Resynchronization therapy (CRT) And AV Node ablation in Atrial Fibrillation Datuk Dr. Azlan Hussin Follow Up
13 PROTECT-ICD Trial: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction Dr. Geetha A/P Kandavello @ Kandhavel Follow Up
14 CRYO AF GLOBAL REGISTRY Dr. Surinder Kaur Khelae Follow Up
15 A DUE: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy Dr. Geetha A/P Kandavello @ Kandhavel Follow Up
16 BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT) Datuk Dr. Shaiful Azmi Yahaya Follow Up
17 MICRA AV: Product Surveillance Registry (PSR) Datuk Dr. Azlan Hussin Follow Up
As at 29 Nov 2022
COMPLETED
Book an Appointment
judi online daftar slot gacor online slot online pragmatic play slot pro thailand